The Contribution of Four Immunogenetic Markers for Predicting Persistent Activity in Patients with Recent-Onset Rheumatoid Arthritis or Undifferentiated Arthritis. (8th August 2011)

• Record Type: Journal Article
• Authors: Reneses, Sonsoles; Fernández-Suárez, Antonio; González-Escribano, Maria F.; Pestana, Luis; García, Alicia
• Other Names: Bruges Armas J. Academic Editor.; Mackworth-Young C. G. Academic Editor.
• Is Part Of: ISRN rheumatology. Volume 2011(2011)
• Publication Date: 2011-08-08
• Subjects: Rheumatology -- Periodicals; Rheumatic Diseases; Rheumatology; Rheumatology; Periodicals; 616.723
• DOI: 10.5402/2011/780356
• Languages: English
• ISSNs: 2090-5467

Abstract

Abstract : We assessed the contribution of four baseline markers—HLA-DRB1 shared epitope (SE), −308 tumor necrosis factor α gene promoter polymorphism, rheumatoid factor, and anticitrullinated peptide antibodies—for predicting persistent activity (DAS28 score ≥2.6) after one year of followup in a cohort of 201 patients with recent-onset rheumatoid arthritis (RA) or undifferentiated arthritis (UA) aged 16 years or older who had a 4-week to 12-month history of swelling of at least two joints. Patients had not been previously treated with corticosteroids or disease-modifying antirheumatic drugs (DMARD). In the best logistic regression model, only two variables were retained: SE positivity and number of DMARD administered (area under the curve = 76.4%; 95% CI: 69.2%, 84.4%;P < 0.001 ). The best linear regression model also included these two variables, explaining only 22.5% of the variability of DAS28 score. In this study, given an equal number of DMARD administered, the probability of persistent activity in patients with recent-onset RA or UA was significantly influenced by SE presence.